Katherine Peters
Overview:
Dr. Katy Peters, MD Ph.D. FAAN is an associate professor of neurology and neurosurgery at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke. Her academic medical career started at Stanford University School of Medicine, receiving an MD and Ph.D. in Cancer Biology. After completing a neurology residency at Johns Hopkins University and a fellowship in cognitive neurosciences, Katy joined the PRTBTC as a neuro-oncology fellow. In 2009, she became a faculty member at PRTBTC. With a fantastic team of nursing and advanced practice providers, she actively sees and cares for patients with primary brain tumors. Her research interests include supportive care for brain cancer patients, cognitive dysfunction in cancer patients, and physical function and activity of brain cancer patients. While she runs clinical trials to treat primary brain tumors, her key interest is on clinical trials that focus on improving brain tumor patients' quality of life and cognition. In 2019, the PRTBTC designated her as the Director of Supportive Care, thus furthering the PRTBTC and her committee to better the quality of life for brain tumor patients. She is active in teaching medical school students, residents, fellows, and advanced practice providers and is the Program Director of the PRTBRC neuro-oncology fellowship. She is board certified by the American Board of Psychiatry and Neurology and the United Council of Neurologic Subspecialties for neuro-oncology.
Positions:
Associate Professor of Neurosurgery
Vice Chair for Education in the Department of Neurology
Associate Professor in Neurology
Member of the Duke Cancer Institute
Education:
M.D. 2003
Ph.D. 2003
Intern, Medicine
Resident and Fellow in Neurology, Neurology
Fellow in Neuro-Oncology, Surgery
Grants:
Ph 1/2 Trial for Patients with Newly Diagnosed High Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001
A Phase 1, Multicenter, Randomized, Controlled, Open-label, Perioperative Study of AG-120 and AG-881 in Subjects with Recurrent, Non-enhancing, IDH1 Mutant, Low-grade Glioma. (AG120-881-C-001)
Functional Capacity and Physical Function in Glioblastoma Patients Treated with or without Tumor-Treating Fields
A Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma receiving Depatuxizumab Mafodotin
A randomized phase 2 single blind study of temozolomide plus radiation therapy combined with nivolumab or placebo in newly diagnosed adult subjects with MGMT-methylated glioblastoma (BMS CA209-548)
Publications:
Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma.
Clinical management of seizures in patients with meningiomas: Efficacy of surgical resection for seizure control and patient-tailored postoperative anti-epileptic drug management.
Novel Mechanisms and Future Opportunities for the Management of Radiation Necrosis in Patients Treated for Brain Metastases in the Era of Immunotherapy.
Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors.
Research Areas:
